Cargando…

Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1

Narcolepsy type 1 is characterised by an increase in body weight after disease onset, frequently leading to obesity. It was suggested that this weight gain may be counteracted by treatment with sodium oxybate. We here provide longitudinal body mass index data of patients with narcolepsy type 1 after...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schinkelshoek, Mink S., Smolders, Isabelle M., Donjacour, Claire E., van der Meijden, Wisse P., van Zwet, Erik W., Fronczek, Rolf, Lammers, Gert Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Hypersomnias
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378953/ https://www.ncbi.nlm.nih.gov/pubmed/29504180 http://dx.doi.org/10.1111/jsr.12684

Ejemplares similares

The development of hypocretin deficiency in narcolepsy type 1 can be swift and closely linked to symptom onset: clues from a singular case
por: Schinkelshoek, Mink Sebastian, et al.
Publicado: (2019)

Sleep, Narcolepsy, and Sodium Oxybate
por: Mamelak, Mortimer
Publicado: (2022)

What triggered narcolepsy: H1N1 vaccination, virus, or both? Important lessons learned from China
por: Gool, Jari K, et al.
Publicado: (2023)

Role of Brown Adipose Tissue in Adiposity Associated With Narcolepsy Type 1
por: Straat, Maaike E., et al.
Publicado: (2020)

Psychosis in Patients with Narcolepsy as an Adverse Effect of Sodium Oxybate
por: Sarkanen, Tomi, et al.
Publicado: (2014)

Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
por: van der Hoeven, Adrienne Elisabeth, et al.
Publicado: (2022)

Off-label Sodium Oxybate in Childhood Narcolepsy: A Comprehensive Report
por: Miskoff, Jeffrey A, et al.
Publicado: (2018)

Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate
por: Schneider, Logan D, et al.
Publicado: (2023)

A Case of Off-label Sodium Oxybate in an 11-Year-Old with Narcolepsy
por: Miskoff, Jeffrey A, et al.
Publicado: (2019)

REM Sleep Behavior Disorder in Children With Type 1 Narcolepsy Treated With Sodium Oxybate
por: Antelmi, Elena, et al.
Publicado: (2021)

Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy
por: Dubow, Jordan, et al.
Publicado: (2022)

O024 Sodium oxybate for refractory narcolepsy and idiopathic hypersomnia: clinical and employment outcomes
por: Hernest, A, et al.
Publicado: (2023)

Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing
por: Feldman, Neil T.
Publicado: (2009)

Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice
por: Drakatos, Panagis, et al.
Publicado: (2017)

Resolution of Sleepwalking Behavior after Initiation of Sodium Oxybate in a Patient with Narcolepsy Type 2
por: Hesselbacher, Sean, et al.
Publicado: (2018)

Population and Noncompartmental Pharmacokinetics of Sodium Oxybate Support Weight‐Based Dosing in Children and Adolescents With Narcolepsy With Cataplexy
por: Chen, Cuiping, et al.
Publicado: (2020)

Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment
por: Morse, Anne Marie, et al.
Publicado: (2023)

Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2020)

Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Corrigendum to: Efficacy and Safety of Calcium, Magnesium, Potassium, and Sodium Oxybates (Lower-Sodium Oxybate [LXB]; JZP-258) in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults With Narcolepsy With Cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Reduced Numbers of Corticotropin‐Releasing Hormone Neurons in Narcolepsy Type 1
por: Shan, Ling, et al.
Publicado: (2022)

Long-term follow-up on the effects of sodium oxybate on daytime sleepiness and sleep architecture in patients with narcolepsy type 1
por: Peraita-Adrados, Rosa, et al.
Publicado: (2023)

Individualized Treatment Patterns for Patients with Narcolepsy Treated with Oxybate: A Clinical Practice Perspective
por: Roy, Asim, et al.
Publicado: (2023)

Sodium Oxybate: a Substitute for Alcohol?
por: Gual, A., et al.
Publicado: (2022)

Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy
por: Kushida, Clete A, et al.
Publicado: (2021)

Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy
por: Bogan, Richard K., et al.
Publicado: (2023)

Widespread white matter connectivity abnormalities in narcolepsy type 1: A diffusion tensor imaging study
por: Gool, Jari K., et al.
Publicado: (2019)

The Sustained Attention to Response Task Shows Lower Cingulo-Opercular and Frontoparietal Activity in People with Narcolepsy Type 1: An fMRI Study on the Neural Regulation of Attention
por: Gool, Jari K., et al.
Publicado: (2020)

School Problems and School Support for Children with Narcolepsy: Parent, Teacher, and Child Reports
por: Janssens, Karin, et al.
Publicado: (2023)

Evaluation of Quality of Life in Patients With Narcolepsy Treated With Sodium Oxybate: Use of the 36-Item Short-Form Health Survey in a Clinical Trial
por: Bogan, Richard, et al.
Publicado: (2016)

Once-nightly sodium oxybate (FT218) in the treatment of narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et al
por: Skobieranda, Franck, et al.
Publicado: (2022)

Response to: Once-nightly sodium oxybate (FT218) in the treatment of narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et al
por: Kushida, Clete A, et al.
Publicado: (2022)

Enhanced Visual Cortex Activation in People With Narcolepsy Type 1 During Active Sleep Resistance: An fMRI-EEG Study
por: Gool, Jari K., et al.
Publicado: (2022)

Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary
por: Rosenberg, Russell, et al.
Publicado: (2023)

Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial
por: Dauvilliers, Yves, et al.
Publicado: (2023)

Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial
por: Roth, Thomas, et al.
Publicado: (2022)

Sodium oxybate—a new horizon for symptomatic treatment of RBD?
por: Stefani, Ambra, et al.
Publicado: (2023)

Evaluation of the Effectiveness of the Risk Minimization Measures of Sodium Oxybate in the European Union
por: Iranzo, Alex, et al.
Publicado: (2020)

Correlation of Changes in Patient-Reported Quality of Life With Physician-Rated Global Impression of Change in Patients With Narcolepsy Participating in a Clinical Trial of Sodium Oxybate: A Post Hoc Analysis
por: Bogan, Richard K., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_68hhlsmms8pu6q7t4o4o20cina